{
    "root": "316a46f1-2d4e-7684-e063-6294a90a2ef8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Solifenacin Succinate",
    "value": "20250328",
    "ingredients": [
        {
            "name": "SOLIFENACIN SUCCINATE",
            "code": "KKA5DLD701"
        }
    ],
    "indications": "Solifenacin Succinate Tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.",
    "contraindications": "5 mg tablet taken orally once daily, and if well tolerated may be increased to 10 mg once daily. ( 2.1 ) Do not exceed the 5 mg dose of Solifenacin Succinate Tablets in patients with: Severe renal impairment creatinine clearance < 30 mL/min/1.73 m 2 . ( 2.2 , 8.6 ) Moderate hepatic impairment (Child-Pugh B). Solifenacin Succinate Tablets are not recommended in patients with severe hepatic impairment (Child-Pugh C). ( 2.3 , 8.7 ) Concomitant use of strong CYP3A4 inhibitors. ( 2.4 , 7.1 )",
    "warningsAndPrecautions": "Solifenacin Succinate Tablets are supplied as round, film-coated tablets, biconvex, available in bottles as follows:\n                  Each 5 mg tablet is yellow, debossed with ‘AP28’ on one side and plain on the other side and is available as follows:\n                  Bottle of 30                 NDC 35561-285-10\n                  Bottle of 90                 NDC 35561-285-11\n                  Bottle of 500               NDC 35561-285-13\n                  \n                  Each 10 mg tablet is yellow, debossed with ‘AP29’ on one side and plain on the other side and is available as follows:\n                  Bottle of 30                 NDC 35561-286-10\n                  Bottle of 90                 NDC 35561-286-11\n                  Bottle of 500               NDC 35561-286-13\n                  Store at 25ºC (77ºF) with excursions permitted from 15ºC to 30ºC (59°F to 86ºF) [see USP Controlled Room Temperature].",
    "adverseReactions": "Solifenacin Succinate Tablets are contraindicated in patients:\n                  \n                     With urinary retention \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.2)]\n        \n  \n   ,\n       \n \n  \n                     With gastric retention \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.3)]\n        \n  \n   ,\n       \n \n  \n                     With uncontrolled narrow-angle glaucoma \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.5)]\n        \n  \n   , and\n       \n \n  \n                     Who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in Solifenacin Succinate Tablets. Reported adverse reactions have included anaphylaxis and angioedema \n        \n  \n   [see \n         \n   \n    Adverse Reactions (6.2)]\n        \n  \n   ."
}